LifeMD, Inc. - 8-K Filing
LifeMD announced a strategic co-marketing collaboration with Antares Pharma, Inc. (a subsidiary of Halozyme) to launch a direct-to-patient self-pay program for XYOSTED® testosterone injection in July 2026 across 37 states. LifeMD will serve as the exclusive telehealth partner and preferred pharmacy for the program, offering patients virtual consultations, lab testing, and home delivery at $249/month. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $LFMDP